# US 2010/0166710 A1 · Compositions and Methods for Inducing Neuronal Differentiation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0166710 A1
- Document ID: US20100166710A1
- Status: Published application
- Kind: A1
- Application number: 12/095,723
- Filed: 2006-12-01
- Published: 2010-07-01
- Earliest claimed: 2005-12-01
- Assignees: The Scripps Research Institute; The Salk Institute for Biological Studies
- Inventors: Masaki Warashina; Kyung Hoon Min; Fred Gage; Peter G. Schultz; Sheng Ding; Tomoko Kuwabara
- Web page: https://patentgrep.com/patent/US20100166710A1

## CPC

- C07D 277/18: Nitrogen atoms
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides compositions and methods for inducing neuronal cell differentiation.

## Claims

### Claim 1

A compound having the structure of Formula I:
and pharmaceutically acceptable salts, and hydrates thereof;
wherein: R1, if present, is selected from the group consisting of C1-8 alkyl, C1-8 haloalkyl, C3-8 cycloalkyl, C2-8 alkenyl, C2-8 alkynyl, halogen, —NO2, —CN, —ORa, —SRa and —NRaRb, wherein Ra and Rb are each independently selected from the group consisting of hydrogen, C1-6 alkyl, C1-6 haloalkyl, C3-8 cycloalkyl, aryl-C0-6 alkyl and heteroaryl-C0-6 alkyl, or when Ra and Rb are attached to the same nitrogen, Ra and Rb can be optionally combined to form a 5- to 7-member heterocycloalkyl ring having from 1-3 heteroatoms selected from the group consisting of N, O and S;
R2, if present, is selected from the group consisting of C1-8 alkyl, C1-8 haloalkyl, C3-8 cycloalkyl, —NO2, —CN, halogen, —C(O)Rd, —C(O)ORd, —C(O)NRdRe, —NRdRe, —S(O)2NRdRe, ORd, SRd, and —NRdC(O)Rf, wherein Rd and Re are each independently selected from the group consisting of hydrogen, C1-6 alkyl, C1-6 haloalkyl, C3-8 cycloalkyl, C2-6 alkenyl, aryl-C0-6 alkyl and heteroaryl-C0-6 alkyl, or when Rd and Re are attached to the same nitrogen, Rd and Re can be optionally combined to form a 5- to 7-member heterocycloalkyl ring having from 1-3 heteroatoms selected from the group consisting of N, O and S; Rf is selected from the group consisting of C1-6 alkyl, C1-6 haloalkyl, C3-8 cycloalkyl, C2-6 alkenyl, C0-6 alkyl-aryl and C0-6 alkyl-heteroaryl;
m and n are each independently an integer from 0 to 4;
R3 is a member selected from the group consisting of hydrogen, C1-8 alkyl, C1-8 haloalkyl, C3-8 cycloalkyl, C1-8 acyl, —SO2—C1-8 alkyl, aryl-C0-4 alkyl and heteroaryl-C0-4 alkyl;
R4, if present, is selected from the group consisting of C1-8 alkyl, halogen, —NO2 and —CN; and
o is an integer from 0 to 1.

### Claim 2 (depends on 1)

The compound of claim 1, wherein said compound has the formula Ia
wherein R1, R2, R3, m and n are defined as set forth in claim 1.

### Claim 3 (depends on 2)

The compound of claim 2, wherein m and n are each 1.

### Claim 4 (depends on 1)

The compound of claim 1, wherein R1 is selected from the group consisting of halogen, C1-8 alkyl and C1-8 haloalkyl.

### Claim 5 (depends on 4)

The compound of claim 4, wherein R1 is selected from the group consisting of chloro, fluoro, bromo, methyl and trifluoromethyl.

### Claim 6 (depends on 1)

The compound of claim 1, wherein m is the integer 0.

### Claim 7 (depends on 1)

The compound of claim 1, wherein R2 is selected from the group consisting of halogen, —C(O)ORd and —C(O)NRdRe, —NRdRe and ORd, wherein Rd and Re are independently selected from the group consisting of hydrogen, C1-6 alkyl and C1-6 haloalkyl, or Rd and Re when attached to the same nitrogen atom are optionally combined to form a 5- to 7-membered heterocycloalkyl ring having from 1-3 heteroatoms selected from the group consisting of N, O and S.

### Claim 8 (depends on 7)

The compound of claim 7, wherein R2 is selected from the group consisting of:

### Claim 9 (depends on 1)

The compound of claim 1, wherein R3 is selected from the group consisting of C1-8 alkyl, C1-8 haloalkyl, C1-8 acyl and C1-4 alkyl-aryl.

### Claim 10 (depends on 9)

The compound of claim 9, wherein R3 is selected from the group consisting of methyl, ethyl, acetyl or benzyl.

### Claim 11 (depends on 1)

The compound of claim 1, wherein R2 is —C(O)ORd and R3 is C1-8 alkyl, m and o are each the integer 0, and n is an integer from 1-2.

### Claim 12 (depends on 3)

The compound of claim 3, wherein R2 on the phenyl ring is para to the nitrogen atom shown in Formula I.

### Claim 13 (depends on 1)

The compound of claim 1, wherein the compound is selected from the group consisting of:

### Claim 14 (depends on 13)

The compound of claim 13, wherein said compound has the structure

### Claim 15 (depends on 1)

A method of inducing neuronal differentiation, the method comprising:
contacting a mammalian cell with a compound of claim 1, whereby the mammalian cell differentiates into a neuronal cell.

### Claim 16 (depends on 1, 15)

The method of claim 15, wherein said compound of claim 1 is in a pharmaceutically acceptable carrier.

### Claim 17 (depends on 15)

The method of claim 15, wherein the mammalian cell is in a mammal.

### Claim 18 (depends on 17)

The method of claim 17, wherein the step of contacting is by oral administration of the compound to the mammal.

### Claim 19 (depends on 17)

The method of claim 17, wherein the step of contacting is by intravenous administration of the compound to the mammal.

### Claim 20 (depends on 17)

The method of claim 17, wherein the step of contacting is by subcutaneous administration of the compound to the mammal.

### Claim 21 (depends on 17)

The method of claim 17, wherein the step of contacting is by intraperitoneal administration of the compound to the mammal.

### Claim 22 (depends on 15)

The method of claim 15, further comprising detecting neuronal differentiation of the mammalian cell.

### Claim 23 (depends on 22)

The method of claim 22, whereby neuronal differentiation of the mammalian cell is detected by detecting expression of a neuronal marker gene.

### Claim 24 (depends on 23)

The method of claim 23, wherein the neuronal marker gene is a gene selected from the group consisting of: TuJ1, NeuroD1, NeuN, neurofilament-H, and Map2.

### Claim 25 (depends on 22)

The method of claim 22, whereby neuronal differentiation of the mammalian cell is detected by detecting downregulation of a neural progenitor marker gene.

### Claim 26 (depends on 25)

The method of claim 25, wherein the neural progenitor marker gene is: Sox2.

### Claim 27 (depends on 15)

The method of claim 15, wherein the mammalian cell is selected from the group consisting of: a neural stem cell and a neural progenitor cell.

### Claim 28 (depends on 27)

The method of claim 27, wherein the stem cell is isolated from a rat.

### Claim 29 (depends on 27)

The method of claim 27, wherein the stem cell is isolated from a primate.

### Claim 30 (depends on 29)

The method of claim 29, wherein the primate is a human.

### Claim 31 (depends on 15)

The method of claim 15, wherein the mammalian cell is attached to a solid support.

### Claim 32 (depends on 1)

A method of treating a neural disorder, the method comprising:
contacting a mammalian cell with a compound of claim 1, whereby the mammalian cell differentiates into a neuronal cell.

### Claim 33 (depends on 32)

The method of claim 32, wherein the neural disorder is a disorder selected from the group consisting of: Alzheimer's disease, Parkinson's disease, multiple sclerosis, and traumatic brain injury.

### Claim 34 (depends on 32)

The method of claim 32, further comprising administering the neuronal cell to an individual with the disorder, thereby treating the disorder.

### Claim 35 (depends on 34)

The method of claim 34, wherein the administration is by surgical implantation.
